ATLASAllianzIM U.S. Equity Buffer20 Oct ETF (OCTW): outlook, holdings and fees
AllianzIM U.S. Equity Buffer20 Oct ETF (OCTW) is an exchange-traded fund and is managed by AllianzIM. The expense ratio is 0.71% and the yield is 0.00%. The ten largest holdings are 153% of the fund.
Fund data as of Oct 14, 2026 · Price Nov 2, 2026
ATLAS view on OCTW
| Last price | $42.01 (+0.1%) |
|---|---|
| ATLAS chance of a higher price in 1 month | 67% |
| Likely 1-month range (50%) | $41.88 – $42.63 |
| Normal 1-day range (±1σ) | ±0.3% |
| Distribution yield | 0.00% |
ATLAS probabilities use the same calibrated model as every stock page. A fair value is shown for companies, not funds; the holdings below link to the fair value of each company.
OCTW fund facts
| Issuer | AllianzIM |
|---|---|
| Theme | Buffered (defined outcome) |
| Assets under management | $339M |
| Expense ratio | 0.71% |
| Number of holdings | 10 |
| Portfolio turnover | 0% |
| Inception | Sep 30, 2020 |
| Exchange | NYSE |
Under normal market conditions, the fund invests at least 80% of its net assets in instruments with economic characteristics similar to U.S. large cap equity securities. Specifically, the Advisor intends to invest substantially all of its assets in FLEX Options that reference the Underlying ETF. The fund is non-diversified.
OCTW top holdings
| Holding | Sector | Weight |
|---|---|---|
| Call Option On Spx 09/30/2021 2185.75 C | – | 124.57% |
| Call Option On Spx 09/30/2021 3651.88 C | – | 22.58% |
| Call Option On Spx 09/30/2021 4371.50 C | – | 4.80% |
| Put Option On Spx 09/30/2021 4371.50 P | – | 0.71% |
| Option on CBOE Mini-Spx Index Xsp Sep21 | – | 0.08% |
| Put Option On Spx 09/30/2021 3362.66 P | – | 0.05% |
| Option on CBOE Mini-Spx Index Xsp | – | 0.01% |
| Put Option On Spx 09/30/2021 2690.15 P | – | 0.01% |
| Option on CBOE Mini-Spx Index Xsp Sep22 | – | 0.00% |
| Option on S&P 500 PR Sep22 | – | 0.00% |
Holdings with an ATLAS page link to their probability range, fair value and earnings calendar.
OCTW sector breakdown
| Sector | Weight |
|---|---|
| Technology | 41.3% |
| Financial Services | 11.3% |
| Communication Services | 9.6% |
| Healthcare | 8.9% |
| Consumer Cyclicals | 8.5% |
| Industrials | 7.2% |
| Consumer Defensive | 4.5% |
| Energy | 3.6% |
| Utilities | 1.9% |
| Real Estate | 1.7% |
| Basic Materials | 1.5% |
By region: North America 99.5%, Europe Developed 0.3%, Asia Emerging 0.1%.
OCTW returns and risk
| Year to date | +8.8% |
|---|---|
| 1 year | +10.7% |
| 3 years (annualised) | +10.9% |
| 5 years (annualised) | +9.3% |
| Volatility (3 years) | 4.7% |
| Sharpe ratio (3 years) | 1.17 |
Past returns do not guarantee future results.
OCTW: frequently asked questions
What does OCTW invest in?
AllianzIM U.S. Equity Buffer20 Oct ETF invests in a portfolio of securities. Its largest holdings are Call Option On Spx 09/30/2021 2185.75 C (124.6%), Call Option On Spx 09/30/2021 3651.88 C (22.6%), Call Option On Spx 09/30/2021 4371.50 C (4.8%), Put Option On Spx 09/30/2021 4371.50 P (0.7%), Option on CBOE Mini-Spx Index Xsp Sep21 (0.1%).
What is the OCTW expense ratio?
0.71% a year: about $71.00 for every $10,000 invested.
What is the OCTW dividend yield?
0.00%. ATLAS does not hold the exact distribution dates for ETFs.
Will OCTW go up?
Nobody can know. The ATLAS model puts the chance of a higher price in one month at 67%, with a likely range (50%) of $41.88 to $42.63 from $42.01 today. It is a probability, not a prediction.
How has OCTW performed?
Year to date +8.8%, one year +10.7%, three years +10.9% a year, five years +9.3% a year. Past returns do not guarantee future results.
Similar ETFs: Buffered (defined outcome)
- FT Vest Laddered Buffer ETF (BUFR)
- Innovator Defined Wealth Shield ETF (BALT)
- FT Vest Laddered Deep Buffer ETF (BUFD)
- FT Vest Laddered Nasdaq Buffer ETF (BUFQ)
- Innovator U.S. Equity Power Buffer ETF - January (PJAN)
- Innovator U.S. Equity Power Buffer ETF - September (PSEP)
- FT Vest Laddered Moderate Buffer ETF (BUFZ)
- Innovator Laddered Allocation Buffer ETF (BUFF)
Educational information, not investment advice. Disclaimer